• Epsolay® and Twyneo® PDUFA goal dates set for April 26, 2021 and August 1, 2021, respectively
• Premium generic product revenue of $ 8.7 million in fiscal 2020
• Additional collaboration agreements for generic products signed with Perrigo, bringing the number of collaborations between companies to 12
NESS ZIONA, Israel, March 4, 2021 (GLOBE NEWSWIRE) – Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical stage dermatology company focused on the identification, development and commercialization of generic and topical pharmaceutical products. skin disease treatment brand, today announced its full-year financial results ended December 31, 2020, and provided company updates.
“I am very satisfied with the main achievements of Sol-Gel last year. After announcing positive data from The Epsolay and Twyneo Phase 3 testing and submission of NDAs to the FDA within guided deadlines, 2020 was highlighted by the positive acceptance of both NDAs and assigned PDUFA dates, “commented Dr Alon Seri-Levy, Administrator Sol-Gel delegate.
“Given the competitive landscape of the dermatology market and the significant capital that would be required to market our products directly, our current operating model assumes that we will partner with a dermatology company that has a strong market presence. This would enable us to acquire market share more quickly without the need to invest in building our own marketing and sales force and would allow us to further invest in …